Exscientia And Sanofi Will Search For 15 Novel Oncology, Immunology Drugs Under New Pact

Building on an alliance dating back to 2016, Exscientia and Sanofi will use artificial intelligence and insights gleaned from patient tissue samples to seek out 15 novel therapies.

Touch the future,Interface technology, the future of user experience.
Exscientia's new team-up with Sanofi seeks to discover 15 novel AI-derived drugs

Artificial intelligence-driven Exscientia Ltd. has signed on a “who’s who” list of biopharma partners over the years, but on 7 January announced a $100m up front, and potentially multi-billion-dollar downstream, extension of its work with Sanofi to apply its precision medicine platform using both AI and patient tissue samples to pursue 15 novel therapies in oncology and immunology.

The new agreement, which builds on the companies’ existing 2016 deal, is just the latest tie-up with big pharma for Exscientia and is part of an accelerating trend of big pharma companies partnering with AI and machine learning-specialty firms for drug discovery and development. For example, Amgen, Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Pharma Left Hanging After US/UK Trade Pact

 
• By 

An ‘historic economic prosperity deal’ does not include the sector.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By 

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

More from Business

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.